NCT03571763Recruiting
The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients
The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients: Prospective, Multi-center, Cohort Study
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1875 (estimated)
- First submitted
- 5 Jun 2018
- Start date
- 1 Aug 2018
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- General Hospital of Shenyang Military Region
- Diseases
- Stroke
- NCT number
- NCT03571763
What you commit to
- Study type: Observational
- Planned participants: 1875
- From 1 Aug 2018 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication for antiplatelet or anticoagulation therapy;
Other illness
- Hemorrhagic transformation after acute Ischemic stroke;
- Severe head trauma or intracranial hemorrhage occurred in the past six months;
Other
- MRI contraindication;
- obvious coagulopathy;
- Other intracranial lesions associated with (such as tumor, cerebral vascular malformation);
- other unqualified patients judged by the investigator
Who the study is looking for
- Patient age ≥18 years;
- Acute ischemic stroke patient confirmed by imaging;
- Time of onset: within 3 months;
- Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke;
- Baseline SWI sequence must have at least one CMB ;
- NIHSS≤10
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| General Hospital of ShenYang Military Region Coordinator of this site? Confirm its status | Shenyang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.